For investors, healthcare innovators, and mental-health advocates — this New to The Street interview features Dr. Jonathan Javitt, Founder & CEO of NRx Pharmaceuticals, discussing major breakthroughs in treating PTSD, suicidal depression, and treatment-resistant mood disorders.
NRx recently received FDA acceptance for its preservative-free ketamine formulation, addressing long-standing safety concerns around traditional ketamine products and setting a July PDUFA decision date. At the same time, the company is expanding beyond drug development with its first Hope Clinic, combining neuroplastic medications with transcranial magnetic stimulation (TMS) and other advanced therapies.
A key highlight is emerging data showing that low-dose cycloserine dramatically amplifies the effectiveness of TMS, increasing remission rates by as much as eight times compared with TMS alone. With existing FDA designations and new clinical protocols underway, NRx believes this approach could fundamentally change outcomes for patients suffering from severe depression, PTSD, and suicidality — particularly among veterans.
Through partnerships with Angel Force USA and direct engagement with military communities, NRx is working to ensure that these innovations translate into real-world impact where the need is greatest.